Pharmadrug Inc.
LMLLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.01 | 0.04 |
| FCF Yield | -76.44% | -21.66% | -41.51% | -31.74% |
| EV / EBITDA | -3.91 | -3.34 | -2.92 | -3.10 |
| Quality | ||||
| ROIC | -557.52% | -412.09% | -19.39% | -14.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -30.75% |
| Cash Conversion Ratio | 0.87 | 0.05 | 0.74 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -77.44% |
| Free Cash Flow Growth | -14.40% | 70.23% | 45.85% | -191.09% |
| Safety | ||||
| Net Debt / EBITDA | -2.19 | -1.02 | -0.60 | 0.02 |
| Interest Coverage | 0.00 | 0.00 | -10.46 | -44.97 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.06 |
| Cash Conversion Cycle | 0.00 | -6,259.31 | -84,724.52 | -2,564.12 |